Report DMCA Phase I study of DFP-11207, a novel oral fluoropyrimidine with reasonable AUC and low C max and improved tolerability, i
* Please fill this form as much details as possible, we will respond to your request within 2 to 3 business days.
* Please fill this form as much details as possible, we will respond to your request within 2 to 3 business days.